Outcomes and complications of transarterial chemoembolization on colorectal cancer with liver metastases

Yıl 2018, Cilt: 15 Sayı: 3, 255 - 258, 12.12.2018

Muhammet Arslan Serkan Değirmencioğlu Muhammed Tekinhatun Atike Gökçen Demiray

Öz

---

Background: To retrospectively evaluate the survival rates effectiveness and complications of transarterial chemoembolization on colorectal cancer with liver metastases.

Material and Methods: Fiftyseven patients (mean age 63) and 112 procedures with colorectal cancer liver metastases retrospectively underwent. Survival times and periprocedural complications were assessed.

Results: The treatment was tolerated well by all patients. Survival rate for 1 and 2 years from first transarterial chemoembolization was 58.4% and 26.5%, respectively. Median survival time was 18.5 months. There were 62 times postembolization syndrome in 32 patients after transarterial chemoembolization. One patient had abscess in liver after chemoembolization.

Conclusions: Transarterial chemoembolization is a minimally invasive treatment for liver metastases of colorectal carcinomas and has little major complications. Transarterial chemoembolization is one of an effective palliative treatment for metastatic colorectal cancer.

Anahtar Kelimeler

metastasis, colorectal carcinoma, liver, chemoembolization

Kolorektal kanserli hastaların karaciğer metastazlarına uygulanan transarteriyal kemoembolizasyon tedavisinin erken dönem sonuçları ve komplikasyonları

Öz

Amaç: Kolorektal kanserli hastaların karaciğer metastazlarına uygulanan transarteriyal kemoembolizasyon tedavisinin sağ kalıma etkisini ve işleme bağlı komplikasyonları değerlendirmeyi amaçladık.

Materyal ve Metod: Ortalama yaşları 63 olan 57 hasta ve 112 transarteriyal kemoembolizasyon işlemi retrospektif olarak tarandı. Dosya kayıtlarından hastaların sağ kalım oranları ve işleme bağlı komplikasyonları değerlendirildi.

Bulgular: Tüm hastalar transarteriyal kemoembolizasyon işlemini tolere etti. Hastalarımızda 1 yıllık sağ kalım oranı %58.4, 2 yıllık sağ kalım oranı 26.5 olarak hesaplandı. Ortalama sağ kalım 18.5 ay olarak bulundu. Toplam 32 hastada 62 kez postembolizasyon sendromu oluştuğu bir hastada ise işlem sonrası hepatik apse oluştuğu belirlendi.

Sonuç: Kolorektal kanserli hastaların karaciğer metastazlarına uygulanan transarteriyal kemoembolizasyon minimal invaziv ve düşük majör komplikasyon oranlarına sahip bir tedavi yöntemidir. Transarteriyal kemoembolizasyon metastatik karaciğerli kolorektal kanserli hastalarda etkili palyatif bir tedavi yöntemidir.

Anahtar Kelimeler

Karaciğer, metastaz, kolorektal kanser, kemoembolizasyon

Kaynakça

• KaynaklarReferans1. Yamashita S, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg 2018;267(3):514-520.Referans2. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010;257:674-684.Referans3. Smith MD, McCall JL. Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases. Br J Surg 2009;96(10):1101-1113.Referans4. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009;250(1):281-289.Referans5. Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: Factors affecting outcomes a 10-year experience at a single center. Radiology 2016;278(2):601-611.Referans6. Yoon SS, Tanabe KK. Multidisciplinary management of metastatic colorectal cancer. Surg Oncol 1998;7:197–207.Referans7. Tellez C, Benson A and Lyster M: Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998;82:1250-1259. Referans8. Nishiofuku H, Tanaka T, Matsuoka M, Otsuji T, Anai H, Sueyoshi S, Inaba Y, Koyama F, Sho M, Nakajima Y and Kichikawa K: Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: Results of a phase I/II study. J Vasc Interv Radiol 2013;24(1):56-65.Referans9. Albert M, Kiefer M, Sun W, Haller D, Fraker DL, Tuite CM, Stavropoulos SW, Mondschein JI and Soulen MC: Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011;117(2):343-352.Referans10. Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S and Benea G: Transarterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC bead, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 2011;31(12):4581-4587.Referans11. Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecaneluting beads: results of a phase II clinical study. In Vivo 2007;21(6):1085-1091.Referans12. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study. Anticancer Res 2012;32:1387-1396.Referans13. Martin R, Scoggins C, Tomalty D, Schreeder M, Metzger T, Tatum C, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: Results of pharmacokinetics and phase I trial. J Gastrointest Surg 2012;16(8):1531-1538.Referans14. Fiorentini G, Aliberti C, Mulazzani L, Coschiera P, Catalano V, Rossi D, et al. Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res 2014;34:575-584.Referans15. Eichler K, Zangos S, Mack MG, Hammerstingl R, Gruber-Rouh T, Gallus C, et al. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol 2012;41(4):1213-1220.Referans16. Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 2015;41:729-741.Referans17. Efthimios A, Bakalakos MD, Julian A, Kim MD, Donn C. Young D, et al. Determinants of survival following hepatic resection for metastatic colorectal cancer. World J. Surg 1998;22:399-405.Referans18. Akhan Okan, Akıncı D, Çiftçi T. Malign Karaciğer Tümörleri: Perkütan Ablasyon. Turkiye Klinikleri J Radiol-Special Topics 2016;9(2):1-8.Referans19. Geyik S, Akhan O, Abbasoğlu O, Akinci D, Ozkan OS, Hamaloğlu E, et al. Radiofrequency ablation of unresectable hepatic tumors. Diagn Interv Radiol 2006;12:195-200.Referans20. Erdogan EB, Ozdemir H, Aydin M. Radioembolization Treatment for Liver Cancer. Bezmialem Science 2016;1:25-32.Referans21. Timothy WI, Clark TW. Complications of hepatic chemoembolization. Semin Intervent Radiol 2006;23:119-125.Referans22. Xia J, Ren Z, Ye S, Sharma D, Lin Z, Gan Y, et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006;59:407-412. Referans23. Tu J, Jia Z, Ying X, Zhang D, Li S, Tian F, et al. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma. Medicine (Baltimore). 2016;95:e5606. Referans24. Lima M, Dutra S, Veloso Gomes F, Bilhim T, Coimbra E. Risk factors for the development of postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma treatment. Acta Med Port 2018;31:22-29.